Outcome of patients with relapsed/refractory acute lymphoblastic leukemia after blinatumomab failure: No change in the level of CD19 expression
Sign Up to like & getrecommendations! Published in 2018 at "American Journal of Hematology"
DOI: 10.1002/ajh.24987
Abstract: Blinatumomab, a bi‐specific T‐cell engaging CD3‐CD19 antibody construct, has shown significant activity in patients with relapsed/refractory (R/R) B‐cell acute lymphoblastic leukemia (ALL). Despite this improvement, most patients relapse. Here, we describe the outcome of 68… read more here.
Keywords: blinatumomab failure; cd19; outcome patients; blinatumomab ... See more keywords